40
Pharma & HealthcareAvoid
Nippon India Pharma
Nippon India · Direct–Growth · rank #13 of 19 by Smart Score
Data updated
Trailing returns
1 Year
10.6%
+12.7% vs index
3 Years
18.6%
+8.7% vs index
5 Years
13.8%
+4.3% vs index
Since launch
17.6%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-9.1%-12.9% vs index
2023
+40.4%+13.8% vs index
2024
+35.3%+19.6% vs index
2025
-2.5%-10.1% vs index
2026
+13.0%+16.6% vs index
Why this score
Nippon India Pharma scores 40/100 — #13 of 19 Pharma & Healthcare fund (Avoid). It stands out for volatility and fund size — beating 91% of peers on volatility. The main drag is its 3y return (better than only 5% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return18.55% · 5th percentile in category
5Y return13.76% · 17th percentile in category
Volatility12.98 · 91st percentile in category
Fund size9479.08 Cr · 97th percentile in category
Sharpe ratio0.93 · 28th percentile in category
1Y return10.63% · 15th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd12.37%
2.Divi's Laboratories Ltd7%
3.Lupin Ltd6.43%
4.Cipla Ltd6.09%
5.Apollo Hospitals Enterprise Ltd5.15%
36 disclosed equity positions · portfolio as of Aug 2026 · weights are % of total corpus.